Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids - PubMed (original) (raw)
Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids
A J Fosang et al. Biochem J. 1995.
Abstract
We have developed a monoclonal antibody AF-28 that specifically recognizes a neo-epitope on polypeptides with N-terminal FFGVG ... sequences. This sequence is found at the N-terminus of aggrecan fragments that have been digested with matrix metalloproteinases (MMPs). By immunoblotting, monoclonal antibody AF-28 specifically detected G2 fragments derived from an aggrecan G1-G2 substrate digested with stromelysin, collagenase, gelatinase and matrilysin, but failed to detect G2 fragments obtained from elastase, trypsin or cathepsin B digests. Undigested G1-G2 was not detected. In addition, AF-28 antibody detected fragments derived from whole aggrecan and this detection did not require prior treatment with chondroitinase or keratanase. Competition experiments confirmed that peptides containing internal ... FFGVG ... sequences were not detected by the antibody, while native MMP-digested aggrecan fragments and a synthetic 32-mer peptide with FFGVG ... N-termini were equally competitive on a molar basis. An FFGVG 5-mer, and an FGVGGEEDI9-mer which lacked the N-terminal phenylalanine residue, were 50 times and 230 times respectively less competitive than the FFGVG ... 32-mer. Two fragments from the interglobular domain, F342-F373 and F342-D441, that are predicted products of G1-G2 digestion by neutrophil collagenase but have not previously been detected, could be detected with AF-28. The epitope recognized by AF-28 was also detected in human synovial fluids by Western blot analysis. A broad band of 100-200 kDa was detected in some patients and a dominant band of 40-60 kDa was found in two patients. The size of this small fragment corresponds with that seen for the porcine F342-E373 product and may represent the natural physiological product of aggrecan cleaved in vivo at both the MMP site (... DIPEN341 decreases F342FGVG ...) and the aggrecanase site (... ITEGE373 decreases A374RGSVI ...).
Similar articles
- Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent.
Fosang AJ, Last K, Maciewicz RA. Fosang AJ, et al. J Clin Invest. 1996 Nov 15;98(10):2292-9. doi: 10.1172/JCI119040. J Clin Invest. 1996. PMID: 8941646 Free PMC article. - The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-d (atrolysin C) at the matrix metalloproteinase and aggrecanase sites.
Tortorella MD, Pratta MA, Fox JW, Arner EC. Tortorella MD, et al. J Biol Chem. 1998 Mar 6;273(10):5846-50. doi: 10.1074/jbc.273.10.5846. J Biol Chem. 1998. PMID: 9488721 - Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum.
Lark MW, Williams H, Hoernner LA, Weidner J, Ayala JM, Harper CF, Christen A, Olszewski J, Konteatis Z, Webber R, et al. Lark MW, et al. Biochem J. 1995 Apr 1;307 ( Pt 1)(Pt 1):245-52. doi: 10.1042/bj3070245. Biochem J. 1995. PMID: 7717983 Free PMC article. - Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Hughes CE, et al. Biochem J. 1995 Feb 1;305 ( Pt 3)(Pt 3):799-804. doi: 10.1042/bj3050799. Biochem J. 1995. PMID: 7531436 Free PMC article.
Cited by
- The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways.
Mort JS, Buttle DJ. Mort JS, et al. Mol Pathol. 1999 Feb;52(1):11-8. doi: 10.1136/mp.52.1.11. Mol Pathol. 1999. PMID: 10439833 Free PMC article. Review. - The innate immune response as a mediator of osteoarthritis pain.
Miller RJ, Malfait AM, Miller RE. Miller RJ, et al. Osteoarthritis Cartilage. 2020 May;28(5):562-571. doi: 10.1016/j.joca.2019.11.006. Epub 2019 Dec 17. Osteoarthritis Cartilage. 2020. PMID: 31862470 Free PMC article. Review. - _Adamts5_-/- Mice Exhibit Altered Aggrecan Proteolytic Profiles That Correlate With Ascending Aortic Anomalies.
Dupuis LE, Nelson EL, Hozik B, Porto SC, Rogers-DeCotes A, Fosang A, Kern CB. Dupuis LE, et al. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2067-2081. doi: 10.1161/ATVBAHA.119.313077. Epub 2019 Aug 1. Arterioscler Thromb Vasc Biol. 2019. PMID: 31366218 Free PMC article. - Osteoarthritis year 2010 in review: biochemical markers.
Kraus VB. Kraus VB. Osteoarthritis Cartilage. 2011 Apr;19(4):346-53. doi: 10.1016/j.joca.2011.02.002. Epub 2011 Feb 12. Osteoarthritis Cartilage. 2011. PMID: 21320614 Free PMC article. Review. - Catabolism of aggrecan, decorin and biglycan in tendon.
Rees SG, Flannery CR, Little CB, Hughes CE, Caterson B, Dent CM. Rees SG, et al. Biochem J. 2000 Aug 15;350 Pt 1(Pt 1):181-8. Biochem J. 2000. PMID: 10926842 Free PMC article.
References
- Biochemistry. 1971 Jun 22;10(13):2606-17 - PubMed
- Biochem J. 1995 Feb 1;305 ( Pt 3):799-804 - PubMed
- Mol Immunol. 1980 Jun;17(6):749-56 - PubMed
- Eur J Biochem. 1986 Jun 2;157(2):385-91 - PubMed
- Anal Biochem. 1986 Jul;156(1):38-44 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous